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Lipid synthesis is under tight transcriptional control involving sterol regulatory element binding proteins (SREBP1, SREBP2). Rising
cellular cholesterol levels prevent SREBP2 from entering the nucleus to directly activate the expression of 3-hydroxy-3-methylglutaryl-
coenzyme A reductase (Hmgcr), the key enzyme of cholesterol synthesis. The failure to down-regulate cholesterol synthesis in gallstone-
susceptible C57L/J but not AKR/J mice prompted us to study the processing of SREBP2 in these mice. Male mice of each strain received a
control or lithogenic diet for 28 days. Membrane and nuclear extracts of pooled livers were prepared for immunoblot analysis of SREBP.
Steady-state mRNA levels of Hmgcr, Srebp1, Srebp2 and the SREBP cleavage activating protein (Scap) were measured from individual
livers. There was no marked difference between the two strains with regard to processing of SREBP1 as well as steady-state mRNA levels of
Srebp1, Srebp2 and Scap. However, a near-complete suppression of nuclear SREBP2 related to low Hmgcr mRNA levels was noticed only
for gallstone-resistant AKR mice. Abnormal regulation of SREBP2 appears to be responsible for the failure to suppress cholesterol synthesis
in genetically cholesterol gallstone-susceptible mice. This defect may contribute to cholesterol hypersecretion and gallstone formation.
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The intracellular lipid balance is maintained by coordi-
nated transcriptional control. For cholesterol, sterol regula-
tory elements are the target of transcription factors
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Stuttgart, Germany.(SREBPs). While SREBP2 is predominantly involved in
cholesterol homeostasis, SREBP1 is also linked to fatty acid
metabolism [1]. SREBPs are synthesized as inactive integral
membrane proteins of the endoplasmic reticulum where they
bind to the cholesterol sensor SCAP or SREBP cleavage-
activating protein [1]. In sterol-depleted cells, the SCAP/
SREBP complex moves from the endoplasmic reticulum to
the Golgi apparatus via sorting into coat protein II-coated
vesicles [2]. The sequential action of Site-1 and Site-2
protease, both residing in the Golgi apparatus, cleaves the
membrane-bound SREBP [1] and allows transport of now
active SREBP into the nucleus for activation of target genes
that aim at increasing intracellular cholesterol availability.
Conversely, when SCAP senses excess cholesterol, the
SCAP/SREBP complex is bound to INSIG, an intrinsic
membrane protein of the endoplasmic reticulum [3]. As a
result, SREBP remains trapped in the endoplasmic reticulum
and loses access to the proteases of the Golgi apparatus so
that the transcription of target genes declines.
Biliary cholesterol hypersecretion appears to be a key
defect that facilitates gallstone formation in C57L/J but not
G. Xu et al. / Biochimica et Biophysica Acta 1688 (2004) 274–279 275AKR/J mice [4]. Although HDL-cholesterol contributes
substantially to biliary cholesterol [5,6], the role of newly
synthesized cholesterol for biliary secretion has not been
explored in these mice. Interestingly, the activity of
hepatic 3-hydroxy-3-methylglutaryl-coenzyme A reductase
(HMGCR), the rate-limiting enzyme in cholesterol syn-
thesis, is not down-regulated in C57L mice fed a lithoge-
nic diet which contains large amounts of cholesterol [7,8].
In the current study, we explored the hypothesis that the
failure of C57L mice to suppress cholesterol synthesis in
response to a lithogenic diet is a result of impaired SREBP
processing. A clear-cut difference between the two mouse
strains was observed for the processing of SREBP2. Upon
feeding the lithogenic diet, nuclear SREBP2 decreased
almost completely in AKR mice. This is in line with the
suppression of Hmgcr mRNA and in agreement with an
intact negative feedback control of cholesterol synthesis.
Contrary, processing of SREBP2 continued in C57L mice
and this was paralleled by a failure to suppress Hmgcr
mRNA. These results suggest that impaired reglation of
SREBP2 may be responsible, at least in part, for the failure
to inhibit cholesterol synthesis in gallstone-susceptible
C57L mice.2. Materials and methods
2.1. Materials
Taq DNA polymerase was purchased from Boehringer
Mannheim (Germany) and primers were obtained from
MWG Biotech (Ebersberg, Germany). Polyclonal rabbit
anti-human SREBP1 and goat anti-human SREBP2 anti-
bodies were purchased from Santa Cruz Biotechnology
(Santa Cruz, USA). It has not been reported that the
SREBP1 antibody used is specific for either of the two
isoforms (SREBP1a, SREBP1c). Horseradish peroxidase-
labeled secondary antibodies were from Dako Chemicals
(Hamburg, Germany). Unless otherwise indicated, materials
of highest purity grade commercially available were ob-
tained from Sigma Chemicals (Deisenhofen, Germany) or
Biometra (Go¨ttingen, Germany).
2.2. Animals
Male AKR/J and C57L/J mice were obtained from The
Jackson Laboratory (Bar Harbor, ME) and maintained
under constant light–dark cycles with free access to water
and standard Altromin 1314 chow ( < 0.02% cholesterol;
Altromin GmbH, Lage, Germany). Twelve-week-old male
animals received either a chow or a lithogenic diet con-
sisting of 15% fat, 1.25% cholesterol and 0.5% cholic acid
[5] for 28 days. All animals received human care accord-
ing to the criteria for the care and use of laboratory animal.
Protocols were approved by the Institutional Animal Care
and Use Committee and euthanasia was consistent withrecommendations of the American Veterinary Medical
Association.
2.3. Immunoblot analysis
Twelve mice of each strain, either fed a standard or
lithogenic diet, were anesthetized with pentobarbital intra-
peritoneally (35 mg/kg body weight). Membranes and
nuclear extracts were prepared from pooled livers of six
mice as previously described by others [9]. Equal quantities
(30 mg) of membrane fractions and nuclear extracts were
subjected to 8% SDS-PAGE and proteins were electropho-
retically transferred onto nitrocellulose. The membranes
were exposed to antibodies against SREBP1 (1:2000 dilu-
tion) and SREBP2 (1:4000 dilution) for at least 2 h.
Detection of immunoreactive protein was accomplished
using a chemiluminescence kit (NEN Life Science) follow-
ing incubation with horseradish peroxidase-labeled second-
ary antibodies. Protein gels were calibrated with prestained
Rainbow markers (Amersham Pharmacia, Freiburg, Ger-
many). The protein content of the samples was measured
as described previously [5].
2.4. RNA analysis
Relative quantitation of transcript abundance employed
reverse transcription-polymerase chain reaction. Due to its
invariant expression across treatment conditions, 18S ribo-
somal RNA was used as internal standard [5]. Total mouse
liver RNA from individual mice (n = 6) was isolated using
TRIzol reagent (Life Technology, Munich, Germany). Re-
verse transcription was performed with the SuperScript II
preamplification system (Life Technology). An aliquot of the
reaction was subjected to PCR amplification using a ‘‘com-
petimer ’’/primer mix specific for 18S ribosomal
RNA (QuantumRNA 18S Internal Standards, Ambion, Aus-
tin, TX) together with the following gene specific
primers: Hmgcr (882 bp): 5V-ATCATCTTGGAGAGA-
TAAAACTGCCA-3V (sense) and 5V-GGGACGGTGA-
CACTTACCATCTGTATGATG-3V (antisense); Ldlr (210
bp): 5V-CTC CTC ATT CCC TCT GCC AGC CAT-3V
(sense), 5V-GAA GTC GAC ACT GTA CTG ACC ACC-3V
(antisense); Acat2 (423 bp): 5V-CAT CTC GCC GAA GGC
GTT GAG-3V(sense), 5V-CGC TGC GTG CTG GTC TTT
GAG-3V(antisense); Cyp7a1 (721 bp): 5V-AAG TCA AAG
GGT CTG GGT AG-3V(sense), 5V-GTC ACG GAA GGG
ATG TAT GC-3V(antisense); Srebp1 (1046 bp): 5V-TCAA-
CAACCAAGACAGTGACTTCCCTGGCC-3V (sense) and
5V-GTTCTCCTGCTTGAGCTTCTGGTTGCTGTG-3V (an-
tisense). The primer set is not specific for the two isoforms
Srebp1a or Srebp1c, respectively; Srebp2 (1342 bp): 5V-
CATGAG(GC)ACCCTCACGGAGCTGGGCGACGA-3V
(sense) and 5V-TGCATCATCCA(AG)(CT)AGAGGAG-
(CT)TCCTGGCTC-3V(antisense); Scap (585 bp): 5V-ACT-
GGGCATCATCCTCATTG-3V(sense) and 5V-GGCACTGT-
CTGGTTCTCTGG-3V (antisense). ‘‘Competimers’’ are
Fig. 1. Immunoblot analysis of SREBP1 and SREBP2 in AKR and C57L
mice fed a control (C) or lithogenic (L) diet. For each group and preparation
(n= 2), livers of six mice were pooled. Aliquots of membranes and nuclear
extracts were subjected to SDS-PAGE and electrophoretically transferred to
nitrocellulose. SREBP1 and SREBP2 were visualized with enhanced
chemiluminescence. M, mature or nuclear form of SREBP; P, precursor or
membrane-bound form of SREBP.
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petimers’’ to primers was adjusted such that the amount of
18S ribosomal RNA product was within the same range as
that of the mRNAs of interest. Amplified samples were
subjected to densitometry following agarose gel electropho-
resis with ethidium bromide staining using a GS-700 Imag-
ing Densitometer and the Molecular Analyst Software
(BioRad). Compared with state-of-the-art quantitative real-
time PCR, this method of mRNA quantification may repre-
sent a weakness. However, control experiments demonstrat-
ed that the PCR protocol employed allowed quantitation
within the linear range of amplification of both transcripts
and yielded similar results when compared with Northern
blot analysis [5].
2.5. Lipid analysis
To determine hepatic total cholesterol and triglycerides
contents, separate groups of four mice were used. Lipids
were extracted as described [10], dissolved in isopropanol,
and aliquots were used for determinations of total choles-
terol and triglycerides employing commercially available
colorimetric kits.
2.6. Statistics
Data were analyzed by the unpaired, two-tailed Stu-
dent’s t test. Results are expressed as the arithmetic
meanF 1 S.D. and P values < 0.05 were considered statis-
tically significant.3. Results
As reported recently by our group [5], body weights of
AKR and C57L mice fed the control diet were similar. In
response to the lithogenic diet, the mean body weight of
C57L remained constant but increased by 30% in AKR
mice. Initial mean liver weights were only slightly higher in
AKR mice. When challenged with the lithogenic diet and in
contrast to the C57L strain, livers of AKR mice appeared
pale and were enlarged, reflected by a 50% increase in the
mean liver weight. The hepatic total cholesterol content was
comparable in chow-fed mice of both strains as well as in
response to the lithogenic diet [5]. The hepatic triglyceride
content on chow diet was slightly higher in the AKR strain
and a significant (P < 0.01) increase occurred in both strains
in response to the lithogenic diet (AKR: 89.0F 4.3; C57L:
42.6F 2.7 mg/g).
Immunoblot analysis was employed to investigate the
effect of the lithogenic diet on the processing of SREBP1
and SREBP2 in livers of AKR and C57L mice (Fig. 1).
Under control conditions, both strains expressed precursor
and nuclear forms of SREBP1 and SREBP2 at a detectable
level. In response to the lithogenic diet, the precursor form
of SREBP1 increased more pronounced in C57L than inAKR mice (180% vs. 37%). At the same time, nuclear
forms of SREBP1 decreased by 70% in the C57L and by
20% in the AKR strain, respectively. As reported previously
by others, SREBP1 bands may appear as closely spaced
doublets [9]. Interestingly, the lower SREBP1 band clearly
present in C57L mice fed the control diet consistently
disappeared upon feeding the lithogenic diet. Because the
polyclonal antibody against SREBP1 does not discriminate
between SREBP1a and SREBP1c isoforms, it is possible
that the lower band may represent one of the two isoforms.
Employing isoform-specific antibodies may provide an
answer.
Precursor forms of SREBP2 increased slightly in both
strains in the lithogenic state. Interestingly and in contrast to
C57L mice, the AKR strain exhibited a nearly complete
absence of nuclear SREBP2. This implicates that impaired
processing of SREBP2 in C57L but not AKR mice may be
responsible for the failure to down-regulate cholesterol
synthesis that has been reported previously [7,8]. To con-
firm impaired feedback regulation of cholesterol synthesis
in C57L mice under our present experimental conditions,
we measured steady-state HmgcrmRNA expression (Fig. 2).
On control diet, steady-state Hmgcr mRNA levels were
threefold (P < 0.001) lower in AKR mice and a 40%
decrease (P < 0.01) occurred in the lithogenic state. In
contrast, C57L mice fed the lithogenic diet were unable to
suppress cholesterol synthesis reflected by unchanged
Fig. 2. Amounts of various mRNAs in livers of AKR and C57L mice a control (C) or lithogenic (L) diet. Total RNA from small parts of livers of the animals
(n= 6) used in Fig. 1 was prepared and steady-state mRNA levels were analyzed by RT-PCR. Signals corresponding to specific mRNAs were quantified by
densitometry. The lower of the two bands represents 18S ribosomal RNA. The fold change in each mRNA, relative to that of mice fed the control diet, was
calculated after correction with 18S ribosomal RNA. These values are shown below a representative gel. Srebp1, sterol regulatory element binding protein 1;
Srebp2, sterol regulatory element binding protein 2; Scap, sterol regulatory element binding protein cleavage activating protein; Hmgcr, 3-hydroxy-3-
methylglutaryl coenzyme A; Ldlr, low density lipoprotein receptor; Acat2, acyl-CoA:cholesterol acyltransferase 2; Cyp7a1, cholesterol 7a-hydroxylase.
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lipid regulatory enzymes augment the bioavailability of free
cholesterol, we also measured steady-state Ldlr, Acat2 and
Cyp7a1 mRNA expression (Fig. 2). Basal steady-state Ldlr
and Acat2 mRNA levels were similar in both strains. When
the animals received the lithogenic diet, Ldlr and Acat2
mRNA levels increased significantly (P < 0.05). AKR mice
had threefold (P < 0.01) higher basal Cyp7a1 mRNA ex-
pression levels than C57L mice. In response to the litho-
genic diet, steady-state Cyp7a1 mRNA levels of C57L and
AKR mice were suppressed by 50% (P < 0.01) and 80%
(P < 0.001), respectively. These results are in line with an
increased bioavailability of free cholesterol in response to
the lithogenic diet.
Regulation of SREBP does not only occur at the
posttranscriptional but also at the transcriptional level.
We also analyzed steady-state Srebp1, Srebp2 and Scap
mRNA levels (Fig. 2). In AKR mice, Srebp1 mRNA
levels were twofold lower than in C57L mice (0.65F
0.04 vs. 1.47F 0.13; P < 0.001) and increased 1.5-fold
(P < 0.01) upon challenge with the lithogenic diet. Basal
Srebp2 mRNA expression levels were also lower in AKR
mice (1.39F 0.16 vs. 2.12F 0.58; P>0.05) and decreased
by 60–70% (P < 0.01) when the animals received the
lithogenic diet. This confirms that SREBP2 activity is
regulated not only posttranslationally by proteolytic cleav-
age of the precursor form, but also at the transcriptional
level [11]. Basal steady-state Scap mRNA levels were 1.4-
fold higher in AKR than in C57L mice (1.67F 0.14 vs.
1.21F 0.03; P < 0.05). Feeding the lithogenic diet resulted
in a 20% (P>0.05) decrease of Scap mRNA levels in both
strains.4. Discussion
The C57L gallstone-susceptible mouse reflects metabolic
abnormalities frequently observed in cholesterol gallstone
patients [12,13]. Detailed characterization of this specific
mouse strain [4,5,8] provided compelling evidence that
HDL-cholesterol contributes substantially to biliary choles-
terol hypersecretion that is crucial to initiate cholesterol
crystallization and gallstone formation. However, employ-
ing other mouse models, the role of HDL cholesterol as
substrate for biliary cholesterol during lithogenesis has been
questioned [14]. C57L mice also fail to suppress mRNA
levels and activity of HMGCR in the lithogenic state [5,7,8],
suggesting that newly synthesized cholesterol further con-
tributes to cholesterol hypersecretion. We hypothesized that
the molecular mechanism that prevents suppression of
HMGCR under these conditions may be related to impaired
proteolytic processing of SREBPs.
In the non-lithogenic state (control diet), steady-state
Hmgcr mRNA levels were significantly lower in AKR than
in C57L mice. This is in good agreement with a previously
reported nearly 50% lower HMGCR activity in AKR mice
[7]. This may suggest that in the face of a dietary challenge
with cholesterol, C57L mice have a reduced ability to
down-regulate HMGCR that normally would compensate
for the increased dietary supply of cholesterol. Unexpect-
edly, we found similar Srebp2 mRNA levels in addition to
expressed nuclear SREBP2 in both mouse strains. One
explanation may be the complex transcription of the
Hmgcr gene with several transcription initiation sites
[15]. It is possible that transcription factors other than
SREBPs or co-regulators such as NF-Y/CBF [16] may
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under these conditions.
In the lithogenic state, the increase of membrane-bound
SREBP1 and the concomitant reduction of nuclear SREBP1
in both mouse strains indicate that the proteolytic process
governing the release of membrane-bound SREBP1 is
intact. Although the SREBP1 antibody used did not allow
us to distinguish between SREBP1a and SREBP1c, the
latter constitutes more than 90% of the SREBP pool in the
mouse [1]. Together with the fact that SREBP1c is a potent
regulator of lipogenesis [1], the more pronounced decrease
of nuclear SREBP1 in C57L compared with AKR mice may
protect them from developing fatty liver [17].
The decrease of nuclear SREBP2 in AKR but not C57L
mice in the lithogenic state is in line with a decline of
steady-state Hmgcr mRNA levels and a suppression of
HMGCR activity [5,7,8]. Although preformed cholesterol
represents a predominant source for biliary cholesterol
[18,19] with a significant contribution of HDL cholesterol
[5,6], our results suggest that the contribution of newly
synthesized cholesterol to lithogenic bile and gallstone
formation is appreciable. Indeed, this is in good agreement
with recent preliminary studies where AKR and C57L mice
were fed the squalene epoxidase inhibitor Tu 2208 in
addition to the lithogenic diet [20]. Under these conditions,
HMGCR activity was suppressed by 40% associated with a
reduction of gallstone prevalence by 50% and a gallstone
mass less than assayable. Further support comes from a
study where the cholesterol saturation index could be
decreased in patients with a history of gallstones by long-
term administration of the HMGCR inhibitor fluvastatin
[21]. Clearly, future studies to measure directly the contri-
bution of newly synthesized cholesterol to biliary choles-
terol under such conditions are needed. Substantial amounts
of dietary fat and cholic acid, both of which can influence
the hepatic regulation of SREBPs, are included in the
lithogenic diet. To better understand the regulation of
SREBPs in gallstone susceptibility, one might suggest using
a diet enriched only in cholesterol. However, such a diet
does not induce gallstone formation in C57L mice [22].
The release of mature SREBP1 and SREBP2 occurs in
the Golgi apparatus and involves two proteases that likely
do not distinguish between SREBP1 and SREBP2, respec-
tively. The decrease of nuclear SREBP2 in AKR mice in the
lithogenic state despite a concomitant decrease of nuclear
SREBP1 represents an interesting mechanistic dilemma.
Putative molecular mechanisms far beyond the scope of
our study may explain this observation and should be
addressed by direct experimentation in the future: (i) a
prolonged nuclear decay of mature SREBP2 in C57L mice
may explain the presence of this transcription factor in the
nuclear compartment and reflects impaired proteasome-
mediated degradation; (ii) sterol-independent cleavage of
SREBP2 as has been reported to occur during apoptosis
[23]; (iii) a mutated SREBP2 escaping sterol sensing that
cannot be suppressed by sterols [24], and (iv) exit of theSCAP/SREBP2 complex from the endoplasmic reticulum
with the inability to turn off proteolysis may impair choles-
terol sensing. This may be related to a mutation in the
cholesterol sensing domain of SCAP [3]. The recent iden-
tification of INSIG1 and INSIG2 isoforms [25] may provide
another explanation. Under conditions of cholesterol excess,
INSIG2 alone is mediating SREBP regulation. Thus, it is
possible that an INSIG2 defect allows continuous process-
ing of SREBP2 but may be insufficient to trap SREBP1 in
the endoplasmic reticulum [26].
In summary, the current study provides first insights how
impaired feedback regulation of SREBP2 processing may
explain, at least in part, why gallstone-susceptible C57L
mice, despite ingestion of large amounts of cholesterol, do
not suppress hepatic cholesterol synthesis. We speculate that
in contrast to the non-lithogenic state, the contribution of
newly synthesized cholesterol to biliary cholesterol secre-
tion and gallstone formation is appreciable. Based on
published quantitative trait locus analysis data for C57L
mice [4], we infer that one or more Lith gene(s) may be
involved in the processing of SREBP2.Acknowledgements
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